Arbutus Biopharma

News

Moderna's settlement of patent litigation with Arbutus and Genevant over technology used in its Spikevax COVID vaccine could reach up to $2.25bn.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.